BiogenedWAR:BGD -0.54%68 FCF Yield % is 7.77 as of Jul. 05, 2026, which is 10% below its 10-year median of 8.59. GuruFocus rates WAR:BGD with a GF Score™ of 68/100 and a GF Value™ of zł23.82 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,004 Drug Manufacturers companies, Biogened ranks better than 83.86% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Biogened FCF Yield % Related Terms
Biogened FCF Yield % Historical Data
* Premium members only.
The historical data trend for Biogened's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:BGD vs ZTS, UTHR, VTRS: FCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biogened's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogened FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biogened's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Biogened's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogened (WAR:BGD) has a FCF Yield % of 7.77 as of Jul. 05, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Biogened and its competitors. This is 10% below median its historical median of 8.59. According to the industry distribution chart, Biogened ranks #162 out of 1004 companies in the Drug Manufacturers industry, placing it in the top 16.1%.
Is Biogened's FCF Yield % too high?
Biogened's current FCF Yield % of 7.77 is 10% below median its 10-year median of 8.59. The Drug Manufacturers industry median FCF Yield % is 0.67. Biogened's value of 7.77 is 1068.4% above this industry median. Based on the distribution chart, Biogened ranks #162 out of 1004 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Biogened has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biogened's FCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biogened ranks #162 out of 1004 companies for FCF Yield %. This places Biogened in the top 16% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 0.67. Biogened's value of 7.77 is 1068.4% above this benchmark. While the company's 10-year median is 8.59 vs. the industry median of 0.67, Biogened has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,004 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biogened's current FCF Yield % of 7.77 is 1068.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Biogened and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogened's current FCF Yield % is 7.77, which is 10% below median its own 10-year median of 8.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogened stock overvalued right now?
Based on GuruFocus' analysis, Biogened (WAR:BGD) is currently considered Modestly Undervalued. The stock's GF Value™ is zł23.82, compared to a current price of zł18.30 — trading 23.2% below its estimated fair value. The current FCF Yield % is 7.77, which is 10% below median its 10-year median of 8.59 and 1068.4% above the Drug Manufacturers industry median of 0.67. Biogened's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Biogened (WAR:BGD), the current FCF Yield % is 7.77 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogened (WAR:BGD) Overvalued in 2026?
Based on GuruFocus' analysis, Biogened stock appears to be undervalued.
The current stock price of zł18.30 is trading 23.2% below its estimated GF Value™ of zł23.82.
GuruFocus considers Biogened to be Modestly Undervalued.
Key valuation signals for WAR:BGD:
FCF Yield %: 7.77 (10% below median its 10-year median of 8.59)
GF Value™: zł23.82 vs. price of zł18.30 (23.2% below fair value)
Industry Position: 1068.4% above the Drug Manufacturers median (#162 of 1004)
No single metric tells the full story. See the WAR:BGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogened SA is involved in manufacturing cosmetic and hygiene products. It also designs, produces, and markets safe, effective dermo-cosmetics under the Dermedic brand. The company's products include Dermocosmetics, Thermal water, and Pharmaceutical manufacturing conditions.
68GF Score
Get the complete analysis for WAR:BGD
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:BGD has been successfully added to your 
